Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With a Solid Tumor or With gBRCA Mutation Ovarian Cancer or Other Solid Tumor

Next Previous
X
Search
Trial Profile

A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With a Solid Tumor or With gBRCA Mutation Ovarian Cancer or Other Solid Tumor

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Lymphoma; Male breast cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms Study 10
  • Sponsors Clovis Oncology [CEASED]; pharmaand GmbH

    • Most Recent Events

    • 08 Dec 2022 Results(n=54; of Parts 2A and 2B from Study 10) assessing Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer published in the British Journal of Cancer
    • 01 May 2022 Results of population pharmacokinetics model Study 1014 (NCT01009190), Study 10 (NCT01482715), and ARIEL2 (NCT01891344) published in the Cancer Chemotherapy and Pharmacology
    • 30 Sep 2021 Results of this post-hoc pooled analysis from Study 10 and ARIEL2 studies assessing molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma published in the Gynecologic Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top